Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib, Pembrolizumab, and TTFields for Recurrent Glioblastoma
NCT05973903Phase 2Withdrawn
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jun 2024
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in glioblastoma (GBM), sponsored by Tel Aviv Sourasky Medical Center. Planned start Jun 2024; status: withdrawn.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05973903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05973903.